What Quotient Biodiagnostics does

AliveDx (formerly Quotient Biodiagnostics) is a publicly traded in-vitro diagnostics (IVD) company that develops, manufactures, and commercializes products for clinical laboratories and healthcare facilities. The company operates three core product brands: MosaiQ, a microarray-based diagnostic platform designed for multiplexed autoimmune and allergy testing; LumiQ, an all-in-one immunofluorescence (IFA) system intended to pair with MosaiQ as a turnkey autoimmune workflow solution; and Alba, a manual reagent product line serving both clinical laboratories and OEM partners. The company reports over 30 years of experience in immunohematology and in-vitro diagnostics, and its legal entity, Quotient Limited, was incorporated in 1992 and listed on NASDAQ in 2017.

The MosaiQ platform is the company's flagship technology and centers on a proprietary microarray architecture that allows multiple tests to be run simultaneously on a single device, with the stated goal of reducing time-to-diagnosis across autoimmune and allergy indications. The MosaiQ menu includes the AiPlex CTDplus (connective tissue disease), AiPlex CD (celiac disease), AiPlex APS (antiphospholipid syndrome), AiPlex VAS (vasculitis), and AllergyPlex assays. MosaiQ and LumiQ together are positioned as an integrated sample-to-result workflow, while Alba functions as a lower-throughput, complementary manual reagent business with distinct pH-change reactions and room-temperature storage.

AliveDx distributes its products through direct sales to clinical laboratories worldwide and through an OEM channel for Alba reagents. The company employs a horizontal segmentation approach targeting clinical labs broadly across autoimmune, allergy, and related clinical fields, and uses a mix of scientific content marketing, industry conference participation (notably ADLM), and direct consultation request forms as primary commercial channels. Quotient Limited rebranded to AliveDx as its commercial identity in 2023 while retaining the legal entity structure and NASDAQ listing under ticker QUOT.

Name

Quotient Biodiagnostics

Legal name

Quotient Limited

Website

https://quotientbd.com

Company type

Public

Founded year

1992

Operating status

Operating

Headcount range

251–500 employees

Short description

AliveDx (formerly Quotient Biodiagnostics) develops and manufactures in-vitro diagnostic products for autoimmune and allergy testing, serving clinical laboratories globally through its MosaiQ microarray platform, LumiQ immunofluorescence system, and Alba reagent line.

Ownership category

akta.pro rank

Product category

In-Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Autoimmune, Allergy & Specialized Immunology Diagnostics (HLAHAAAK)

akta.pro secondary industries

Autoimmune & Allergy Diagnostics (HLAAALAK), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• In-vitro diagnostics
• Microarray immunoassays
• Immunohematology reagents
• Autoimmune disease testing
• Clinical laboratory solutions

Headquarters

HQ city

Newtown

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Distribution channels2 records

Marketing channels4 records

Core offering

Quotient Biodiagnostics (commercially AliveDx) develops and manufactures in-vitro diagnostic products for clinical laboratories. Its portfolio centers on the MosaiQ microarray platform for multiplexed autoimmune, allergy, connective tissue, vasculitis, and celiac disease testing, the LumiQ all-in-one immunofluorescence (IFA) solution, and the Alba manual reagent product line for immunohematology and blood banking workflows.

Product overview

AliveDx (formerly Quotient Biodiagnostics/Quotient Limited) offers a portfolio of in-vitro diagnostic solutions designed to promote lab productivity and deliver economic and clinical value for faster disease detection and diagnosis. The product portfolio centers on three main brands: MosaiQ (a microarray diagnostic platform for autoimmune diseases, allergy, and beyond), LumiQ (an all-in-one immunofluorescence IFA solution that complements MosaiQ), and Alba (a manual reagent product line with technical support). With over 30 years of experience in immunohematology and in-vitro diagnostics, the company addresses clinical and laboratory challenges in autoimmune, allergy, and related clinical fields worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• MosaiQ: Automated microarray immunoassay platform for rapid in-vitro diagnostic testing in autoimmune diseases, allergy, and related clinical fields. Designed to shorten time-to-diagnosis with multiple tests on a single platform.
• LumiQ
• Alba

Products and services

• MosaiQ A microarray-based in-vitro diagnostic platform designed to shorten time-to-diagnosis for patients by providing faster test results. The single solution performs multiple tests and provides maximum flexibility to laboratorians and clinicians, focusing on autoimmune diseases, allergy, and clinical diagnostics.
• LumiQ An all-in-one Immunofluorescence (IFA) solution designed to provide workflow efficiency from patient sample in to result out. When combined with MosaiQ, it serves as a turnkey automated autoimmune solution.
• Alba A manual reagent product line backed by expert technical support and reliable customer service. Includes elution kits, OEM solutions, and various reagent products for clinical laboratory use, with features such as distinct pH change reactions and room temperature storage.
• AiPlex CTDplus Assay An assay designed for use with the MosaiQ microarray platform, targeting connective tissue diseases via multiplexed testing.
• AiPlex CD Assay An assay for celiac disease diagnostics on the MosaiQ microarray platform.
• AiPlex APS Assay An assay for antiphospholipid syndrome testing on the MosaiQ microarray platform.
• AiPlex VAS Assay An assay for vasculitis diagnosis on the MosaiQ microarray platform, detecting ANCA-associated vasculitis markers via multiplexed testing.
• AllergyPlex Assay An allergy testing assay for the MosaiQ microarray platform, enabling multiplexed allergy diagnostics on a single solution.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Werfen (Inova Diagnostics): Specializes in autoimmune disease diagnostics including IFA and multiplex platforms (e.g., BIO-FLASH, Aptiva), directly overlapping AliveDx's MosaiQ and LumiQ franchises across connective tissue disease, vasculitis and celiac testing.
• Euroimmun (PerkinElmer): Global autoimmune diagnostics vendor offering IFA, ELISA and microarray/multi-parameter testing; competes head-to-head with AliveDx in autoimmune labs and shares the microarray + IFA integration theme.
• Trinity Biotech: Public IVD company developing autoimmune, infectious disease and hemoglobin diagnostics; comparable in scale, public-market profile and autoimmune focus, making it a near-direct investment comparable for AliveDx.

Broad incumbents

• Bio-Rad Laboratories: Diversified life science and clinical diagnostics company with a significant autoimmune and immunohematology portfolio (e.g., BioPlex 2200) that competes with MosaiQ's multiplex positioning while offering broader menu and global reach.
• Abbott Diagnostics: Major diagnostics incumbent with extensive autoimmune, allergy and immunohematology menus on ARCHITECT and Alinity platforms; competes on workflow consolidation, scale and global lab relationships.
• Roche Diagnostics: World-leading IVD provider (cobas, Elecsys) covering autoimmune, allergy and immunohematology; represents the scale and menu breadth benchmark that AliveDx must differentiate against.
• Thermo Fisher Scientific (Phadia/ImmunoCAP): Operates the Phadia/ImmunoCAP allergy platform, directly overlapping AliveDx's AllergyPlex offering, while also supplying a broad IVD and life sciences portfolio to clinical labs.
• Siemens Healthineers: Major IVD incumbent (ADVIA Centaur, Atellica) with autoimmune and allergy assays; comparable as a competing integrated platform vendor targeting high-volume reference labs.

Emerging players

• Aesku.Diagnostics: Specialized autoimmune diagnostics vendor offering IFA and ELISA assays; comparable in niche focus to AliveDx but smaller scale and more limited menu.
• ImmunoConcepts: Autoimmune diagnostics company focused on IFA reagents and instrumentation for connective tissue disease and infectious disease serology; an adjacent niche player with overlapping customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/153816191323323
• LinkedInlinkedin.com/company/quotient-biodiagnostics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds10 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quotient Biodiagnostics